KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Debt Repayments (2016 - 2017)

Nektar Therapeutics has reported Long-Term Debt Repayments over the past 8 years, most recently at $3.0 million for Q4 2017.

  • Quarterly results put Long-Term Debt Repayments at $3.0 million for Q4 2017, up 422.32% from a year ago — trailing twelve months through Sep 2018 was $3.0 million (up 8.94% YoY), and the annual figure for FY2017 was $5.1 million, down 13.69%.
  • Long-Term Debt Repayments for Q4 2017 was $3.0 million at Nektar Therapeutics, up from $790000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for NKTR hit a ceiling of $3.0 million in Q4 2017 and a floor of $569000.0 in Q4 2016.
  • Median Long-Term Debt Repayments over the past 5 years was $876500.0 (2014), compared with a mean of $1.1 million.
  • Peak annual rise in Long-Term Debt Repayments hit 422.32% in 2017, while the deepest fall reached 64.42% in 2017.
  • Nektar Therapeutics' Long-Term Debt Repayments stood at $791000.0 in 2013, then rose by 21.11% to $958000.0 in 2014, then surged by 44.99% to $1.4 million in 2015, then crashed by 59.04% to $569000.0 in 2016, then surged by 422.32% to $3.0 million in 2017.
  • The last three reported values for Long-Term Debt Repayments were $3.0 million (Q4 2017), $790000.0 (Q3 2017), and $756000.0 (Q2 2017) per Business Quant data.